323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis.

Saved in:
Bibliographic Details
Title: 323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis.
Authors: Kümmel, S1 (AUTHOR), Tondini, C A2 (AUTHOR), Abraham, J3 (AUTHOR), Nowecki, Z I4 (AUTHOR), Itrych, B5 (AUTHOR), Hitre, E6 (AUTHOR), Karaszewska, B7 (AUTHOR), Juarez, A8 (AUTHOR), Morales-Vásquez, F9 (AUTHOR), García, J M Pérez10 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy272.313